Class II · Moderate risk Terminated
Scopolamine Hydrobromide 0.25% Oph Solution
Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Transderm Scop
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application.
What was recalled
Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 24 patches Multi pack, Rx only, Marketed by Baxter Healthcare Cop/Novartis, Deerfield, IL 60015, Manufactured by:Alza Corporation, Vacaville, CA 95688 for Novartis Consumer Health Inc., Parsippany, NJ 07054
- Recalling firm
- Sandoz Inc
- Origin
- NJ, United States
- Initiated by
- Voluntary: Firm initiated
- FDA recall number
- D-0133-2017
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Other Scopolamine recalls
See all
Class II · Moderate risk Terminated
Transderm Scop
Reason cGMP deviations: Temperature abuse
Class II · Moderate risk Terminated
Scopolamine Transdermal Therapeutic System
Reason Defective delivery system
Class II · Moderate risk Terminated
Transderm Scop
Reason Labeling: Incorrect Instructions:outer carton contains the incorrect instructions for Step 2 stating "Do cut the patch" rather than the correct instructions of "Do not cut the patch". The pouch containing the patch is labeled correctly.
Class III · Low risk Terminated
Donnatal
Reason Labeling: Not elsewhere classified - Product label incorrectly lists Scopolamine Hydrocodone as an active ingredient on the side panel instead of Scopolamine Hydrobromide.
Get an alert if your medication is recalled
Tell us which medications you take. If the FDA recalls one, we email you - in plain English, with what to do. Free.